Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Physicians’ Education Resource®, LLC, designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hours.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Jazz Pharmaceuticals, Inc.

Oncology Briefings™: Navigating Novel Emerging Chemotherapeutic Regimens for Patients with ALL

Release Date: October 29, 2021
Expiration Date: October 29, 2022

Activity Overview

This online activity is designed to provide a concise and focused overview of the treatment of pediatric, adolescent, and adult patients given a diagnosis of acute lymphoblastic leukemia (ALL). This activity includes information on risk stratification, the role of chemotherapy and chemotherapeutic combinations in managing this disease, and evolving approaches for treating patients with relapsed/refractory (RR) ALL. The engaging, multimedia format of this program includes audio commentary from an expert thought leader that is integrated with text-based elements.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Jazz Pharmaceuticals, Inc.

Instructions for This Activity and Receiving Credit

Complete the activity (including pre- and post-activity assessments).
Answer the evaluation questions.
Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational initiative is directed toward medical oncologists, hematologists, and other healthcare professionals who treat patients with ALL. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, fellows, and other health care professionals interested in the treatment of ALL will also be invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

Delineate methods to stratify risk among pediatric and adult patients with ALL
Explain the role of chemotherapy, as well as chemotherapeutic combinations, for the management of pediatric and adult patients with newly diagnosed ALL
Discuss evolving approaches for the treatment of relapsed and/or refractory ALL in pediatric and adult patients

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource^®, LLC have no relevant financial relationships with ineligible entities

Faculty

Rachel E. Rau, MD
Physician, Leukemia Program
Texas Children's Cancer Center
Assistant Professor
Department of Pediatrics
Section of Hematology-Oncology
Baylor College of Medicine
Houston, TX

Disclosures: Consultant: Jazz Pharmaceuticals, Servier Pharmaceuticals; Other Support: Travel: Jazz Pharmaceuticals.

PER^® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.